Details of the Drug Combination

General Information of Drug Combination (ID: DCXL8IX)

Drug Combination Name
Diethylcarbamazine Moxidectin
Indication
Disease Entry Status REF
Lymphatic Filariasis Phase 3 [1]
Component Drugs Diethylcarbamazine   DM1TJ8F Moxidectin    DMYGHX5
Small molecular drug N.A.
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Diethylcarbamazine
Disease Entry ICD 11 Status REF
Elephantiasis N.A. Approved [2]
Loiasis N.A. Approved [2]
Lymphatic filariasis 1F66.3 Approved [3]
Onchocerciasis 1F6A Approved [2]
Diethylcarbamazine Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Arachidonate 5-lipoxygenase (5-LOX) TT2J34L LOX5_HUMAN Inhibitor [6]
------------------------------------------------------------------------------------
Diethylcarbamazine Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cytochrome P450 2C19 (CYP2C19) OTFMJYYE CP2CJ_HUMAN Increases Activity [7]
------------------------------------------------------------------------------------
Indication(s) of Moxidectin
Disease Entry ICD 11 Status REF
Onchocerciasis 1F6A Approved [4]
River blindness 1F6A.0 Approved [5]
Moxidectin Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Onchocerca Glutamate-gated chloride channel (Onchoc GluCl) TTSNVHO Q25634_ONCVO Modulator [5]
Gamma-aminobutyric acid receptor (GAR) TTNJYV2 NOUNIPROTAC Modulator [5]
------------------------------------------------------------------------------------
Moxidectin Interacts with 2 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Decreases Expression [8]
Broad substrate specificity ATP-binding cassette transporter ABCG2 (ABCG2) OTW8V2V1 ABCG2_HUMAN Increases Export [9]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT04410406) Moxidectin for LF, Cote d'Ivoire (DOLF)
2 Diethylcarbamazine FDA Label
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 FDA Approved Drug Products from FDA Official Website. 2018. Application Number: (ANDA) 210867.
5 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
6 Inhibition of leukotriene formation by diethylcarbamazine modifies the acid-base balance in the rabbits with blast injuries of the lungs. Vojnosanit Pregl. 1999 May-Jun;56(3):243-7.
7 Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos. 2001 Jan;29(1):30-5.
8 Reversal effects of two new milbemycin compounds on multidrug resistance in MCF-7/adr cells in vitro. Eur J Pharmacol. 2011 Jun 1;659(2-3):108-13. doi: 10.1016/j.ejphar.2011.03.023. Epub 2011 Mar 31.
9 In vitro and in vivo interaction of moxidectin with BCRP/ABCG2. Chem Biol Interact. 2009 Jun 15;180(1):106-12. doi: 10.1016/j.cbi.2009.02.009. Epub 2009 Feb 23.